Core Insights - A newly approved antibody drug from Regeneron Pharmaceuticals effectively eliminates residual traces of multiple myeloma after initial treatments, which may enable patients to avoid intensive bone marrow transplants [1] Company Summary - Regeneron Pharmaceuticals has developed an antibody drug that targets multiple myeloma, a type of blood cancer, showcasing the company's commitment to innovative cancer therapies [1]